AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01530503
Drug: capecitabine and mitomycin
RxNorm normalized name: Capecitabine
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food plus bolus IV infusion mitomycin C 6 mg/m2 day 1.~Cycles will be repeated in both arms every 3 weeks till progression, unacceptable toxicity, medical decision or patient's refusal or for a maximum of 6 months
Trial: NCT03122145
Drug: Capsaicin
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will inspire deeply through the nebulizer coupled to the facemask and pneumotachograph. Each test inhalation will be separated by an interval of 2 minutes. This experimental trial consists of six (instead of 8) test solutions: 0, 25, 50, 100, 200 and 500 μM capsaicin in 80% physiological saline, 20% ethanol. Participants will inhale single vital capacity breaths of capsaicin solution via an air-powered dosimeter (KoKoDigidoser; Pulmonary Data Services Instrumentation Inc; Louisville, CO). The reflex cough test ends when the participant coughs at least 2 times in response to one inhalation dose, or receives a dose of the highest concentration (500 μM).
Trial: NCT01958775
Drug: GLP-2
RxNorm normalized name: (Gly2)GLP-2
DrugBank: Teduglutide (DB08900)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: single subcutaneous dose of 1500mcg
Trial: NCT01356797
Drug: hypobaric levobupivacaine with fentanyl
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SSSA with 4 mg hypobaric levobupivacaine 0,13% with 10 mcg fentanyl
Trial: NCT01356797
Drug: hyperbaric bupivacaine 0,5%
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SUSA with 4 mg hyperbaric bupivacaine 0.5%
Trial: NCT02319031
Drug: Daclatasvir
RxNorm normalized name: Daclatasvir
DrugBank: Daclatasvir (DB09102)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00625391
Drug: GTP+TC
RxNorm normalized name: TC-6987
DrugBank: TC-6987 (DB14854)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg GTP daily plus TC exercise (3x/week) for 24 weeks
Trial: NCT02319031
Drug: Sofosbuvir
RxNorm normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02319031
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03960151
Drug: Rolapitant
RxNorm normalized name: Rolapitant
DrugBank: Rolapitant (DB09291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rolapitant 180mg PO, Days 1 and 5
Trial: NCT03960151
Drug: Palonosetron
RxNorm normalized name: Palonosetron
DrugBank: Palonosetron (DB00377)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palonosetron 0.25 mg IV, Days 1,3, and 5.
Trial: NCT03960151
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine 10 mg PO PM, Days 2,3,4,5,6-8
Trial: NCT03960151
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 20 mg AM, Days 1,2 and 3
Trial: NCT01795976
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine given 25mg/m2 day -5 to day -1
Trial: NCT02656394
Drug: GL101
RxNorm normalized name: Immunoglobulin G1 [296-cysteine,301-glycine,306-cysteine], anti-(human triggering receptor expressed on myeloid cells 2) (human monoclonal VGL101 γ1-chain), disulfide with human monoclonal VGL101 κ-chain, dimer
DrugBank: Iluzanebart (DB18275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Gel
Trial: NCT03297684
Drug: Aflibercept Injection [Eylea]
RxNorm normalized name: aflibercept Injection [Eylea]
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal injection aflibercept
Trial: NCT00475085
Drug: aprepitant
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally or IV
Trial: NCT00475085
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally or IV
Trial: NCT00475085
Drug: granisetron hydrochloride
RxNorm normalized name: Granisetron Hydrochloride
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally or IV
Trial: NCT00475085
Drug: palonosetron hydrochloride
RxNorm normalized name: Palonosetron Hydrochloride
DrugBank: Palonosetron (DB00377)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given orally or IV
Trial: NCT00475085
Drug: prochlorperazine
RxNorm normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally or IV
Trial: NCT01088295
Drug: Telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00939887
Drug: PF-04455242
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of up to 30 mg PF-04455242, delivered in capsule.
Trial: NCT02453750
Drug: Bronchodilator Response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A bronchodilator (Salbutamol 200 mcg or 2 puffs inhaled via spacer device) will be administered to all subjects in the pulmonary function laboratory. 15 minutes after administration of the bronchodilator spirometry will be repeated. This is performed routinely in CDH clinic and is not an additional test for this study.
Trial: NCT01627626
Drug: Pilocarpine
RxNorm normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.1% pilocarpine solution which diluted 2% pilocarpine hydrochloride eyedrop with 0.9% saline.~subjects were instructed to mouthwash with 10ml of solution for 1 minute.
Trial: NCT01627626
Drug: saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.9% saline solution
Trial: NCT01900522
Drug: ITI-214 Dose A
RxNorm normalized name: Arthur Itis
DrugBank: ITI-214 (DB15039)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITI-214 Dose A Oral Solution
Trial: NCT01900522
Drug: ITI-214 Dose B
RxNorm normalized name: Arthur Itis
DrugBank: ITI-214 (DB15039)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITI-214 Oral Solution Dose B
Trial: NCT01900522
Drug: ITI-214 Dose C
RxNorm normalized name: Arthur Itis
DrugBank: ITI-214 (DB15039)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITI-214 Dose C Oral Solution
Trial: NCT01900522
Drug: ITI-214 Dose D (Elderly)
RxNorm normalized name: Arthur Itis
DrugBank: ITI-214 (DB15039)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITI-214 Dose D (Elderly) Oral Solution
Trial: NCT01900522
Drug: ITI-214 Dose E
RxNorm normalized name: Arthur Itis
DrugBank: ITI-214 (DB15039)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITI-214 Dose E Oral Solution
Trial: NCT01900522
Drug: ITI-214 Dose F
RxNorm normalized name: Arthur Itis
DrugBank: ITI-214 (DB15039)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITI-214 Dose F Oral Solution
Trial: NCT01900522
Drug: ITI-214 Dose G
RxNorm normalized name: Arthur Itis
DrugBank: ITI-214 (DB15039)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITI-214 Dose G Oral Solution
Trial: NCT01900522
Drug: ITI-214 Dose H
RxNorm normalized name: Arthur Itis
DrugBank: ITI-214 (DB15039)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITI-214 Dose H Oral Solution
Trial: NCT01673854
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00334737
Drug: Darbepoetin Alfa Injection
RxNorm normalized name: darbepoetin alfa Injection
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: darbepoetin alfa injection 10 mics/kg once a week SC for 10 weeks or until 35 completed weeks
Trial: NCT00334737
Drug: erythropoietin alfa injection
RxNorm normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epo 400 units/kg 3 x weekly SC for 10 weeks or until 35 completed weeks gestation
Trial: NCT00334737
Drug: sham injection
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
DrugBank: Bean (DB14709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sham injection other names: not applicable
Trial: NCT03950544
Drug: Fosfomycin
RxNorm normalized name: FOSFOMYCIN
DrugBank: Fosfomycin (DB00828)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fosfomycin and meropenem
Trial: NCT03950544
Drug: Polymyxin B
RxNorm normalized name: Polymyxin B
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polymyxin B and meropenem
Trial: NCT01720875
Drug: Vorinostat Velcade Dexamethasone
RxNorm normalized name: Velcade
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01905943
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bendamustine: 90 milligram per millilitre square (mg/m\^2) IV over 60 minutes once daily (QD) Day 1-2 in participants previously untreated or 70 mg/m\^2 I.V. over 60 minutes QD Day 1-2 in participants with relapsed/refractory disease. In non-fit participants only, investigators may opt at their own discretion to use lower initial doses of bendamustine, i.e., bendamustine 70 mg/m\^2 in previously untreated participants, and bendamustine 50 mg/m\^2 in relapsed/refractory subjects (over 60 minutes qd Day 1-2 for each administration).
Trial: NCT01905943
Drug: Chlorambucil
RxNorm normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorambucil 0.5 mg/kg p.o. qd on Day 1 and Day 15 in non-fit participants only.
Trial: NCT00369551
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT00369551
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01905943
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine 25 mg/m\^2 I.V. over 30 minutes QD Day 1-3 or Fludarabine 40 mg/m\^2 per os (p.o.) QD Day 1-3 in fit participants only.
Trial: NCT01905943
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive obinutuzumab 1000 mg IV infusion on Days 1/2 (dose split over 2 consecutive days; 100 mg on Day 1 and 900 mg on Day 2), 8 and 15 of cycle 1, and on Day 1 of Cycles 2, 3, 4, 5, and 6. Each cycle is of 28-days duration.
Trial: NCT00626782
Drug: Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab 0.5mg (0.05mL)one injection in sub-tenon's at the conclusion of glaucoma surgery
Trial: NCT00626782
Drug: Mitomycin (MMC)
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin (MMC) C 0.4 mg/ml applied with soaked pledget inserted in the sub-tenon's space during glaucoma surgery.
Trial: NCT00416494
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 85 mg/m2 intravenously over 2 hours on day 1.
Trial: NCT02574078
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02574078
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02574078
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02574078
Drug: nab-Paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02574078
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02574078
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04348448
Drug: Canakinumab 150 MG/ML [Ilaris]
RxNorm normalized name: canakinumab 150 MG/ML [Ilaris]
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: COVID-19
Trial: NCT00275561
Drug: Fluticasone
RxNorm normalized name: Fluticasone
DrugBank: Fluticasone (DB13867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized swallowed fluticasone 880 mg twice a day
Trial: NCT02574078
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00725218
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline 5 ml injection 10 min prior to propofol administration.
Trial: NCT00725218
Drug: Flurbiprofen Axetil
RxNorm normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen Axetil 50 mg in 5 ml injection 10min prior to propofol administration.
Trial: NCT02574078
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02574078
Drug: Crizotinib
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02574078
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00193011
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel
Trial: NCT00193011
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-Fluorouracil
Trial: NCT00145210
Drug: Nebivolol and Atenolol
RxNorm normalized name: valsartan and nebivolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03266991
Drug: Rifapentine
RxNorm normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment with weekly rifapentine and isoniazid as Directly Observed Therapy in 12 weeks
Trial: NCT03266991
Drug: Isoniazid
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment with daily isoniazid in 6 months
Trial: NCT00763165
Drug: Triclosan
RxNorm normalized name: Triclosan
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brush twice daily
Trial: NCT00763165
Drug: Fluoride
RxNorm normalized name: Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brush twice daily
Trial: NCT00660972
Drug: Raltegravir
RxNorm normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 400 mg tablet taken orally twice daily
Trial: NCT00660972
Drug: Emtricitabine/tenofovir disoproxil fumarate
RxNorm normalized name: Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fixed dose tablet containing 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate taken once daily. FTC/TDF will not be provided by the study and must be obtained by the particpant's health care provider.
Trial: NCT00031889
Drug: Exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exemestane
Trial: NCT00031889
Drug: Exemestane+bicalutamide
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exemestane as in arm I and oral bicalutamide once daily
Trial: NCT00648596
Drug: sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sildenafil 50 mg tablet by mouth 1 hour before sexual activity for 12 weeks; the dose could be increased to 100 mg or decreased to 25 mg.
Trial: NCT01544751
Drug: Low dose metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg twice a day
Trial: NCT01544751
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1000 mg twice a day
Trial: NCT00196690
Drug: Donepezil
RxNorm normalized name: Donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01544751
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg/day
Trial: NCT00699556
Drug: 21mg transdermal nicotine patch (Nicoderm CQ)
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 21mg transdermal nicotine patch
Trial: NCT00699556
Drug: 1mg nicotine nasal spray
RxNorm normalized name: nicotine Metered Dose Nasal Spray
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: two 0.5mg/sprays, one to each nostril (dose = 1mg) The nicotine nasal spray is formulated by the Investigational Drug Service at Yale-New Haven Hospital. It is similar in concentration to Nicotrol.
Trial: NCT02299557
Drug: Oxymetazoline gel
RxNorm normalized name: oxymetazoline Nasal Gel
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxymetazoline gel applied intra-anally once daily
Trial: NCT00109395
Drug: Lorazepam
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score
Trial: NCT00662831
Drug: Fragmin/ Dalteparin Sodium
DrugBank: Dalteparin (DB06779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-filled syringes containing a single dose of 5000 IU Fragmin/ Dalteparin Sodium.
Trial: NCT00662831
Drug: Placebo for Fragmin/ Dalteparin Sodium
DrugBank: Dalteparin (DB06779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-filled syringes containing a single dose of placebo for 5000 IU Fragmin/ Dalteparin Sodium.
Trial: NCT03360682
Drug: Lamivudine 300 MG
RxNorm normalized name: lamivudine 300 MG
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine 300 MG/day (48 weeks)
Trial: NCT03360682
Drug: Abacavir 600 MG
RxNorm normalized name: abacavir 600 MG
DrugBank: Abacavir (DB01048)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abacavir 600 MG/day (48 weeks)
Trial: NCT00109395
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score
Trial: NCT00109395
Drug: Lorazepam CI
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score
Trial: NCT03360682
Drug: Dolutegravir 50 mg
RxNorm normalized name: dolutegravir 50 MG
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dolutegravir 50 MG/day (48 weeks)
Trial: NCT03360682
Drug: Tenofovir Disoproxil 245Mg Tablet
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir 245 MG/day (48 weeks)
Trial: NCT03360682
Drug: Emtricitabine 200 MG
RxNorm normalized name: emtricitabine 200 MG
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Emtricitabine 200 MG/day (48 weeks)
Trial: NCT02322580
Drug: etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01434901
Drug: Bethanechol (25 mg)
DrugBank: Bethanechol (DB01019)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
Trial: NCT01434901
Drug: Bethanechol (50 mg)
DrugBank: Bethanechol (DB01019)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
Trial: NCT01434901
Drug: Bethanechol (100 mg)
DrugBank: Bethanechol (DB01019)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
Trial: NCT01734798
Drug: gemcitabine and cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02964273
Drug: Tolvaptan
RxNorm normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tolvaptan spray-dried, immediate release tablets
Trial: NCT02964273
Drug: Tolvaptan Matching-placebo
RxNorm normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tolvaptan matching-placebo tablets
Trial: NCT00575055
Drug: Bapineuzumab 0.5 mg/kg
DrugBank: Bapineuzumab (DB11715)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: given by infusion every 13 weeks for a total of 6 infusions.
Trial: NCT02205190
Drug: Fimasartan
RxNorm normalized name: Fimasartan
DrugBank: Fimasartan (DB09279)
FDA approved: no
EMA approved: no
PMDA approved: no